Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Astellas commences unsolicited tender offer to acquire common shares of OSI for $52.00 per share

Astellas commences unsolicited tender offer to acquire common shares of OSI for $52.00 per share

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Combination treatment strategies may benefit patients with non-small cell lung cancer

Combination treatment strategies may benefit patients with non-small cell lung cancer

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

FDA extends Tarceva's sNDA review period

FDA extends Tarceva's sNDA review period

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

U.S. PTO grants reissue patent concerning OSI Pharmaceuticals’ Tarceva

U.S. PTO grants reissue patent concerning OSI Pharmaceuticals’ Tarceva

New compound may halt drug-resistant lung cancer

New compound may halt drug-resistant lung cancer

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

OSI Pharmaceuticals provides update to ODAC meeting

OSI Pharmaceuticals provides update to ODAC meeting

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Phase 2 clinical study of STA-9090 in NSCLC initiated

Phase 2 clinical study of STA-9090 in NSCLC initiated

FDA Advisory Committee votes against the approval of Tarceva

FDA Advisory Committee votes against the approval of Tarceva

Updated NCCN Guidelines include maintenance therapy for patients with metastatic disease

Updated NCCN Guidelines include maintenance therapy for patients with metastatic disease

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented